Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Leases (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Leases for 5 consecutive years, with $2.0 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases changed N/A year-over-year to $2.0 million; the TTM value through Mar 2026 reached $2.0 million, changed N/A, while the annual FY2025 figure was $2.1 million, N/A changed from the prior year.
  • Operating Leases hit $2.0 million in Q1 2026 for Phathom Pharmaceuticals, down from $2.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $2.1 million in Q3 2025 and bottomed at $133000.0 in Q2 2024.
  • Average Operating Leases over 5 years is $1.1 million, with a median of $1.0 million recorded in 2022.
  • Year-over-year, Operating Leases tumbled 83.14% in 2024 and then soared 342.86% in 2025.
  • Phathom Pharmaceuticals' Operating Leases stood at $1.1 million in 2022, then crashed by 57.92% to $462000.0 in 2023, then crashed by 71.21% to $133000.0 in 2024, then soared by 1452.63% to $2.1 million in 2025, then fell by 5.04% to $2.0 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $2.0 million, $2.1 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.